Benztropine
- Atc Codes:N04AC01
- CAS Codes:132-17-2#86-13-5
- PHARMGKB ID:132-17-2#86-13-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Inhibits
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
North America
Canada: Benztropine; USA: Benztropine, Cogentin.
Drug combinations
Chemistry
Benztropine Mesylate: C~21~H~25~NO CH~4~O~3~S. Mw: 403.53. (1) 8-Azabicyclo[3.2.1]octane, 3-(diphenylmethoxy)-, endo, methanesulfonate; (2) 3α-(Diphenylmethoxy)-1αH,5αH-tropane methanesulfonate. CAS-132-17-2; CAS-86-13-5 (benztropine).
Pharmacologic Category
Antiparkinsonian Agents; Anticholinergic Agents. (ATC-Code: N04AC01).
Mechanism of action
Possesses both anticholinergic and antihistaminic effects. Animal data suggest its antihistaminic activity and duration of action approach that of pyrilamine maleate. May also inhibit the reuptake and storage of dopamine (prolongs the action of dopamine).
Therapeutic use
Adjunctive treatment of Parkinson’s disease. Treatment of drug-induced extrapyramidal symptoms (except tardive dyskinesia).
Pregnancy and lactiation implications
Use with caution during pregnancy and lactation.
Unlabeled use
Contraindications
Hypersensitivity to benztropine or any component of the formulation. Pyloric or duodenal obstruction, stenosing peptic ulcers. Bladder neck obstructions. Achalasia. Myasthenia gravis. Children <3 years of age.
Warnings and precautions
May cause anhidrosis and hyperthermia, which may be severe. May be associated with confusion or hallucinations (generally at higher dosages), CNS depression, and in mental disorders, intensification of symptoms or toxic psychosis. When given in large doses or to susceptible patients, may cause weakness and inability to move particular muscle groups. Use with caution in tachycardia, cardiac arrhythmias, hypertension, hypotension, gastrointestinal obstructive disease, glaucoma, hepatic impairment, prostatic hyperplasia and/or urinary stricture or retention, or renal impairment. Does not relieve symptoms of tardive dyskinesia.